Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Blueprint Medicines Ord Shs (NQ: BPMC)
74.04 USD  -1.28 (-1.70%)
Official Closing Price  /  Updated: 7:34 PM EDT, Aug 11, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 317,464
Open 75.64
Bid (Size) 70.50 (2)
Ask (Size) 74.46 (1)
Prev. Close 75.32
Today's Range 74.00 - 76.68
52wk Range 43.29 - 91.25
Shares Outstanding 43,837,337
Dividend Yield N/A
Performance
YTD
-9.92%
-9.92%
1 Month
-3.41%
-3.41%
3 Month
+16.92%
+16.92%
6 Month
+17.41%
+17.41%
1 Year
-16.90%
-16.90%
Featured News
More News
Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion. Read More
category General , TPTX , BPMC , and 19 more.
from MarketWatch
Cancer stocks heat up after third big merger in the past month
The third multibillion-dollar buyout of cancer-treatment developers in the past month was a charm for the shares of targeted oncology companies, as Leerink analyst Andrew Berens said Eli Lilly’s deal... Read More
category SPX , CELG , Pharmaceuticals , and 24 more.
from MarketWatch
More News
Read More
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
from PR Newswire
Blueprint Medicines Reports Second Quarter 2020 Financial Results
from PR Newswire
Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
from PR Newswire
Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020
from PR Newswire
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
from PR Newswire
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
from PR Newswire
Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
from PR Newswire
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST
from PR Newswire
Recap: Blueprint Medicines Q2 Earnings
category Market News , BPMC , News , and 2 more.
from Benzinga
Analysts Expect FTXH To Hit $28
category ETFs
from ETF Channel
First Week of September 18th Options Trading For Blueprint Medicines (BPMC)
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.